YOUR SEARCH FOR Text 260 RESULTS
251 of Total
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido
View all news Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed
252 of Total
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced An
View all news Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer December 22, 2025 at 2:42
253 of Total
Incyte to Present at Upcoming Investor Conference | Incyte
View all news Incyte to Present at Upcoming Investor Conference December 18, 2025 at 8:00 AM EST PDF Version WILMINGTON, Del. --(BUSINESS WIRE)--Dec
254 of Total
0001673776-26-000006 | 4 | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 4 Filing Date Jan 21, 2026 Document Date Jan 16, 2026 Form
255 of Total
0002039219-26-000002 | 4 | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 4 Filing Date Jan 21, 2026 Document Date Jan 16, 2026 Form
257 of Total
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapse
259 of Total
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced An
260 of Total
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido